Home » Newsletters » BioWorld Science

BioWorld Science

July 25, 2014

View Archived Issues

Neurotrope Bioscience licenses IP for Niemann-Pick Type C disease therapy

MorphoSys and Galapagos advance joint antibody program

Boehringer Ingelheim establishes a research alliance with the University of Toronto

HIV latency reversal achieved in patients with romidepsin

Camelid single-chain antibodies detect AD markers

ArmaGen forms strategic agreement with Shire to develop drug for Hunter syndrome

Phase II results presented for crenezumab for the treatment of AD

Wanbang completes first preclinical studies of SBM-TFC-039

Alios BioPharma's nucleoside analogue shows efficacy in phase II RSV study

Welichem terminates asset purchase agreement for WBI-1001

OncoSynergy reports novel anti-integrin beta1 MAbs

Enrollment complete in phase II trial of lirilumab in AML

Xoma discloses novel anti-FGFR-4 MAbs

EMA accepts MAA for asfotase alfa as a treatment for hypophosphatasia

Novel boron-containing beta-lactamase inhibitors disclosed by Rempex Pharmaceuticals

Incyte reports topline results from RELIEF trial of ruxolitinib

Researchers in Hungary and Switzerland design novel PLK1 inhibitors

Sarah Cannon Research UK and BioMarin collaborate on EMBRACA study

HPV immunotherapy VGX-3100 achieves phase II primary efficacy endpoint

Halozyme resumes enrollment and dosing in PEGPH-20 program

First vaccine candidate for malaria accepted for E.U. regulatory review

BioAlliance Pharma and Topotarget merger now legally effective

Nymox reports efficacy findings from repeat injection phase III study of NX-1207 for BPH

CTD Holdings closes private placement to advance Trappsol Cyclo

FDA accepts Sandoz's BLA for biosimilar filgrastim

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...